Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to down-regulate VEGF expression in esophageal cancer patients
by thalidomide, so to improve their chemoradiotherapy effect. Patients with esophageal cancer
receiving chemoradiotherapy were divided into different sub-group according to dynamic change
of their VEGF level,and those showed increased or unchanged VEGF were added thalidomide at
random. Efficacy and side effect of thalidomide combined with chemoradiotherapy were
evaluated, and at the same time, activity of thalidomide on esophageal cancer and its
clinical safely were assessed.